WhatsApp used in research, but is this ethical?

By HEOR Staff Writer

March 15, 2023

Globally, WhatsApp Messenger has emerged as one of the world’s fastest-growing MIM applications. It has particularly high penetration rates in India, Indonesia, Malaysia, Brazil and South Africa.

The sub-Saharan African region is characterized by mixed migration flows and multiple health challenges, due to the inequalities experienced in access to healthcare disproportionately affect many groups including migrants and mobile populations. Given the existing structural factors impeding access to healthcare, coupled with high rates of mobile telephone use across the sub-Saharan African region; mobile phones are consistently recognized as having great potential for improving access to healthcare in this context.

WhatsApp was largely used in one of two ways for health research; to send hyperlinks to online surveys, or to deliver and evaluate, either an intervention designed for healthcare users or a communication programme for healthcare providers.

Challenges include efforts taken to ensure privacy, confidentiality and anonymity when using WhatsApp as a data collection tool; significant gender divide in access to mobile phones, with men being far more likely to have access to a device than women; features in WhatsApp that could potentially allow some encrypted messages to be read by unintended recipients, compounding the possible breaches of WhatsApp data.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This